Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

Item

http://www.wikidata.org/entity/Q32055417

Q32055417

about

Genetically engineered Newcastle disease virus for malignant melanoma therapy Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses Biological response modifiers in cancer The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Anal melanoma Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.Malignant melanoma (non-metastatic).Clinical implications of the new biology in the development of melanoma vaccines.Advances in cancer vaccine development.Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells Treatment of malignant melanoma.The diversity of T-cell co-stimulation in the induction of antitumor immunity.Oncolytic viruses as novel anticancer agents: turning one scourge against another.Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo.Advances in the non-surgical treatment of melanoma.Use of adjuvant therapy in cutaneous melanoma.Noninterferon-based adjuvant therapy for high-risk melanoma.Vaccines and melanoma.Adjuvant therapy for high-risk primary and resected metastatic melanoma.Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer Melacine: an allogeneic melanoma tumor cell lysate vaccine.Vaccinia as a vector for gene delivery.Oncolytic viral therapies.Replication-selective oncolytic viruses in the treatment of cancer.A review of evidence-based treatment of stage IIB to stage IV melanoma.Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice Biology of human cutaneous melanoma Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.Oncolytic viral therapy of malignant glioma Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.Use of attenuated paramyxoviruses for cancer therapy.Clinical development directions in oncolytic viral therapy.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Melanoma vaccines: developments over the past 10 years.Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease.Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity.

P2860

Q24597831-462314C5-4230-4AD5-AE0E-450524E4A84E Q24631361-06933D2C-1471-4F7F-B730-C92BD471CB55 Q24685049-926509F8-487F-4F2F-BB2E-034CF8C70326 Q30423165-ED4F27ED-6009-431B-ADB5-5B8CA372956C Q30434822-134FE140-03DE-41B9-862A-93A8F9A83B3A Q30437650-5E609535-2E23-4C71-9156-3F513B8D138F Q33184877-2EF3B720-76B8-41FF-A0C6-C08B97AB570B Q33448157-EA6F8A4D-60AF-4453-BEF2-CA5F776C3B93 Q33603062-DEF603C3-5571-4C07-8AC7-C02F9091EF64 Q33603404-87D52778-0B30-4A5C-A938-37B4BCA162AF Q33645792-7242C473-C2BE-4CE5-AD1D-E684067BFF9A Q33689227-5A573CE3-56C1-4B1D-9576-76AE3F4AB27E Q33776121-3B573705-4EC0-4278-B310-9388B8E6C39D Q34074708-74A62BD7-F048-4AD4-AF10-C92B9CC3F141 Q34427532-6FD52653-755B-433B-919F-676616AAD80B Q34481976-38EF22D0-FA52-43A2-8A0D-68C015E73C12 Q34734220-BEAD8A1C-5041-4AE6-9856-C3911845CEF0 Q34969252-E258EB45-99AB-47CE-895A-989AD7A9726B Q35015870-251B4AA0-6696-45D9-BF3C-115760EC4D74 Q35048323-82556EC0-3E40-4E86-8BBB-4AE7BE6C3A23 Q35050645-CAF7BDF6-72BC-47EA-ADF1-4D64ECEF9943 Q35194168-9FB91F34-6672-4CFC-8E04-A5E6814CAEC0 Q35790868-37048396-A808-4EF6-9DCF-7F31138467C0 Q35852258-10386C31-3DF8-4AE8-A84E-4B021EC1DDFE Q35912403-5952FF08-C53C-49A7-9D6E-9EBFCA812A3A Q36229746-DD2CB432-240E-484A-B768-9968F29974B0 Q36580203-770B8DC8-C3FB-4689-BB15-605D6E16EDAC Q37307195-B6E88A13-EBA3-442B-B29B-A9C1E5D0A68B Q37354177-1A001804-F2A2-4BD5-86F8-2332881B4348 Q37533665-F2D68682-AD03-4B57-936D-1A91D66816A7 Q37560757-76EF4841-0D5C-49BB-A74E-7024AD44E252 Q37810599-9BE23E0D-EBBE-4E08-996C-27014BBD1E64 Q37857659-1E50EC3C-CC6A-4D91-9952-C6394E96F075 Q37873932-C4F5919F-EBC9-4103-B24B-DDBC8274C1F8 Q37892595-31B9EC24-A9DD-45B1-B3C2-E20DA51AE24A Q38085677-2E2E67A6-F93E-4DFB-9EA0-32BF05BDE3CA Q38194135-2C91C932-EBC5-42A6-B9E0-7A378C9DDF25 Q42673382-085B604D-1EF0-44F0-9E67-C2116DA0F082 Q44855149-55EA1B28-E720-487C-9C5A-C2FC5E2ED593

P2860

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

Item

http://www.wikidata.org/entity/Q32055417

description

1998 nî lūn-bûn

@nan

1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu